efavirenz and mk 4965
efavirenz has been researched along with mk 4965 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Felock, PJ; Flynn, JA; Lai, MT; Liang, Y; Liu, M; McGaughey, G; Miller, M; Moyer, G; Munshi, V; Perlow-Poehnelt, R; Prasad, S; Reid, JC; Sanchez, R; Sisko, JT; Torrent, M; Tucker, TJ; Tynebor, RM; Vacca, JP; Wan, BL; Williams, TM; Yan, Y | 1 |
| DiStefano, DJ; Hazuda, DJ; Lai, MT; McKenna, PM; Miller, MD; Munshi, V; Touch, S; Tucker, TJ; Tynebor, RM; Williams, TM | 1 |
| Anderson, KD; Anthony, NJ; Bahnck, C; DiStefano, DJ; Felock, PJ; Flynn, JA; Lai, MT; Liang, Y; Lim, JJ; Lu, M; Miller, M; Moyer, G; Munshi, V; Perlow-Poehnelt, R; Rudd, D; Sanchez, R; Su, DS; Tinney, E; Touch, S; Vacca, JP; Wan, BL; Williams, TM; Young, MB | 1 |
Other Studies
3 other study(ies) available for efavirenz and mk 4965
| Article | Year |
|---|---|
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Topics: Administration, Oral; Animals; Bromine Compounds; Crystallography, X-Ray; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Molecular Structure; Mutation; Nucleosides; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2008 |
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Nitriles; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
Topics: Animals; Cell Line; Dogs; Ethers; HIV Reverse Transcriptase; HIV-1; Humans; Macaca mulatta; Mutation; Nucleosides; Rats; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2009 |